Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and pediatric patients with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or
one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or
diluted, the solution may become cloudy, and the onset of action/time to peak effect
may be altered in an unpredictable manner. Do not administer Lantus® via an
insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices
and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®,
and may be life-threatening.

A reduction in the Lantus® dose may be required in patients with renal or hepatic
impairment.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of
thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of
heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Adverse Reactions

In elderly patients with diabetes, dosing should be conservative to avoid hypoglycemia. Hypoglycemia may be difficult to recognize in the elderly.

Important Safety Information for Lantus®SoloSTAR®

Lantus®SoloSTAR® is a disposable prefilled insulin pen. To help ensure
an accurate dose each time, patients should follow all steps in the Instruction
Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin,
which may affect their blood glucose.

Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and pediatric patients with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or
one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or
diluted, the solution may become cloudy, and the onset of action/time to peak effect
may be altered in an unpredictable manner. Do not administer Lantus® via an
insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices
and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®,
and may be life-threatening.

A reduction in the Lantus® dose may be required in patients with renal or hepatic
impairment.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of
thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of
heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Adverse Reactions

In elderly patients with diabetes, dosing should be conservative to avoid hypoglycemia. Hypoglycemia may be difficult to recognize in the elderly.

Important Safety Information for Lantus®SoloSTAR®

Lantus®SoloSTAR® is a disposable prefilled insulin pen. To help ensure
an accurate dose each time, patients should follow all steps in the Instruction
Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin,
which may affect their blood glucose.

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Dosing guidelines and titration for Lantus®

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Structure Titration to Target Fasting Glucose

The dose of Lantus® should be adjusted according to blood glucose measurements to reach fasting plasma glucose (FPG) goal. The dosage of Lantus® should be individualized under the supervision of a treating
healthcare professional in accordance with the needs of the patient.

Hypoglycemia may warrant a dose reduction

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment

aOther titration options are available. Lantus® should be used with oral antidiabetic drugs or rapid-acting insulin

Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and pediatric patients with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or
one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or
diluted, the solution may become cloudy, and the onset of action/time to peak effect
may be altered in an unpredictable manner. Do not administer Lantus® via an
insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices
and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®,
and may be life-threatening.

A reduction in the Lantus® dose may be required in patients with renal or hepatic
impairment.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of
thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of
heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Adverse Reactions

In elderly patients with diabetes, dosing should be conservative to avoid hypoglycemia. Hypoglycemia may be difficult to recognize in the elderly.

Important Safety Information for Lantus®SoloSTAR®

Lantus®SoloSTAR® is a disposable prefilled insulin pen. To help ensure
an accurate dose each time, patients should follow all steps in the Instruction
Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin,
which may affect their blood glucose.

Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and pediatric patients with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or
one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Important Safety Information for Lantus®SoloSTAR®

Lantus®SoloSTAR® is a disposable prefilled insulin pen. To help ensure
an accurate dose each time, patients should follow all steps in the Instruction
Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin,
which may affect their blood glucose.

*"Certified Diabetes Educator" and "CDE" are certification marks owned and registered by the National Certification Board for Diabetes Educators (NCBDE). NCBDE is not affiliated in any way with Sanofi US (or your official designation). NCBDE does not sponsor or endorse any diabetes-related products or services.

Indications and Usage for Lantus®

(insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control
in adults and pediatric patients with type 1 diabetes mellitus and in
adults with type 2 diabetes mellitus. Lantus® should be administered once a
day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of
diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus®

(insulin glargine [rDNA origin] injection)

ContraindicationsLantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions
Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength,
manufacturer, type, or method of administration may result in the need for a change
in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution.
If mixed or diluted, the solution may become cloudy, and the onset of action/time
to peak effect may be altered in an unpredictable manner. Do not administer Lantus®
via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin
devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®,
and may be life-threatening.

A reduction in the Lantus® dose may be required in patients with
renal or hepatic impairment.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of
thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of
heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Important Safety Information for Lantus®SoloSTAR®

Lantus®SoloSTAR® is a disposable prefilled insulin
pen. To help ensure an accurate dose each time, patients should follow all steps
in the Instruction Leaflet accompanying the pen; otherwise they may not get the
correct amount of insulin, which may affect their blood glucose.